Navigation Links
PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
Date:3/7/2011

crease over the approximately 48,800 patients who were on therapy at the end of December 2009 and that cumulatively 78,800 patients have been treated with Tysabri in the post-marketing setting.  Tysabri royalties are determined at a flat rate as a percent of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, wil
    '/>"/>

  • SOURCE PDL BioPharma, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
    5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
    6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
    8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
    9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
    10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
    11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... SETAUKET, N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, ... where its Phase I trial of Lixte,s lead compound, LB‑100, ... institutions. John S. Kovach , M.D., the ... was planned to be completed at a single site. Accrual ...
    (Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
    (Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
    Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
    ... sodium injection) were also ... within 90 days-, BRIDGEWATER, N.J., Dec 10 ... total hospital,direct medical costs associated with VTE treatment are ... the use of low-molecular weight heparin,(LMWH) vs. unfractionated heparin ...
    ... 10 Alfacell Corporation,(Nasdaq: ACEL ) today reported ... The company recorded a net loss of approximately ... for the fiscal quarter ended Oct. 31,compared to a ... and diluted,common share, for the first quarter of fiscal ...
    Cached Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
    (Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
    (Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
    (Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
    (Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
    (Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
    Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... folic acid fortification of enriched grains in the mid 1990s, ... and Canada with neural tube defects has declined by 20 ... institution of fortification, however, the rate at which new cases ... report researchers at the Jean Mayer USDA Human Nutrition Research ...
    ... of the journal Cancer Cell, published by Cell Press ... promyelocytic leukemia (APL) and identifies promising new avenues to ... ,Results from two new studies provide key mechanistic ... deadly type of leukemia.,APL is a cancer of the ...
    ... issue of the journal Cancer Cell, published by Cell ... potency and effectiveness of a tumor necrosis factor (TNF) ... , A new study identifies a combination ... promising treatment currently being used in clinical trials. ...
    ... to boost fruit and vegetable intake among young children could have ... Janet Cade and colleagues of Leeds University assessed the impact of ... 3,700 young students from 98 schools in the north of England. ... and nutrient intake. , It was seen that ...
    ... protect against the clustering of abnormal body chemistry known as ... of Epidemiology and Community Health. ,The syndrome has been ... and premature death. ,The findings are based on ... 59, all of whom were part of a long term ...
    ... Brandeis University study published in the July issue of ... require screening for substance abuse and mental health in ... , This may be a missed opportunity to ... only a fraction of whom currently receive treatment. ...
    Cached Medicine News:Health News:Folicacid Fortification Very Beneficial 2Health News:Folicacid Fortification Very Beneficial 3Health News:Insights into Acute Promyelocytic Leukemia 2Health News:Insights into Acute Promyelocytic Leukemia 3Health News:New Cancer Therapy in Clinical Trial 2Health News:Britains Free Fruit -And -Vegetable -Scheme Falls Flat 2Health News:Screening for Behavioral Health 2
    Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
    Blunt tipped forceps with small, slightly rounded tips angled perpendicular to the shaft. For grasping peripheral membranes....
    ... Microdiathermy System features an advanced design, solid ... as well as many years of clinical ... optimum choice for the placement of discrete ... burns produce the maximum effect at the ...
    Anterior chamber protein cell meter. Laser flare meter and cell-counting functions are included in this cell meter, with dramatically enhanced measurement of cell volume....
    Medicine Products: